Dulaglutide
Dulaglutide is a peptide-based medication used in the treatment of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists, which influence hormonal pathways involved in blood glucose regulation and appetite control.
Dulaglutide is developed and marketed by Eli Lilly and Company under the brand name Trulicity.
The drug is administered as a once-weekly injectable therapy and is used to improve glycemic control in adults with type 2 diabetes, often in combination with lifestyle interventions and other diabetes medications.
Because of its mechanism of action, dulaglutide peptide has also been studied for its effects on weight management and cardiovascular risk factors.
How Dulaglutide peptide works
Dulaglutide acts as an agonist of the GLP-1 receptor, mimicking the activity of the naturally occurring hormone glucagon-like peptide-1. Activation of this pathway may:
stimulate insulin secretion when blood glucose levels are elevated
reduce the release of glucagon, a hormone that increases blood glucose
slow gastric emptying, which can moderate post-meal glucose levels
increase satiety signals, which may reduce food intake
Through these mechanisms, dulaglutide helps regulate glucose metabolism and energy balance.
Because it is engineered with a modified structure that extends its half-life, dulaglutide can be administered once per week, allowing sustained activation of the GLP-1 receptor.
Clinical trials and evidence
Dulaglutide has been evaluated in multiple clinical trials examining its effectiveness in type 2 diabetes management. Clinical studies have investigated:
improvements in HbA1c and blood glucose control
changes in body weight and metabolic markers
effects on cardiovascular outcomes in people with diabetes
Large clinical trials have shown that dulaglutide can significantly improve glycemic control and may reduce the risk of certain cardiovascular events in high-risk patients.
These findings supported its approval by major regulatory authorities for the treatment of type 2 diabetes.
Possible side effects of Dualglutide:
Because dulaglutide influences gastrointestinal and metabolic pathways, the most commonly reported side effects are gastrointestinal symptoms. Reported side effects may include:
nausea
vomiting
diarrhea
decreased appetite
abdominal discomfort
These symptoms are often most noticeable during the early stages of treatment and may decrease over time.
In rare cases, more serious side effects have been reported, which is why treatment with dulaglutide should be prescribed and monitored by a qualified healthcare professional.
References:
– Dulaglutide: First Global Approval, Sanford, 2014 – Drugs (Springer, AdisInsight), https://link.springer.com/article/10.1007/s40265-014-0320-7
– Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND), Gerstein et al., 2019 – The Lancet, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/abstract
– Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes, Bonora et al., 2021 – Diabetes, Obesity and Metabolism (AWARD‑11), https://dom-pubs.onlinelibrary.wiley.com/doi/am-pdf/10.1111/dom.14465